DOC Updates

There are multiple options now for slowing the progression of chronic kidney disease. In part 5 of our special series, host Dr. Neil Skolnik takes a case-based approach to explore treatment options for CKD.

This special episode is sponsored with support from Bayer.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Holly Kramer, MD, MPH, Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, Illinois

Selected References:

Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 https://doi.org/10.2337/dc26-S011

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 doi.org/10.1056/NEJMoa2025845

Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 doi.org/10.1056/NEJMoa2024816

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 doi.org/10.1056/NEJMoa2403347

Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023;46(9):1574–1586 https://doi.org/10.2337/dci23-0030

The Kidney Failure Risk Equation - https://kidneyfailurerisk.com/

Welcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month on DOC Updates:

Oser, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. October 2026; doi.org/10.1056/NEJMoa2608571

Islet autoantibody screening identifies early-stage type 1 diabetes across Europe, Need-To-Know Institute press release

Yang, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis. JAMA. Published online October 2026. doi.org/10.1001/jama.2026.19921

Jastreboff, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. September, 2026. doi.org/10.1056/NEJMoa2604169

Bellido, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Volume 408, Issue 10563. doi.org/10.1016/S0140-6736(26)01861-1

Colhoun, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. European Heart Journal. 2026; ehag524, doi.org/10.1093/eurheartj/ehag524

Garvey, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology, 2026; 14, 914-926. doi.org/10.1016/S2213-8587(26)00213-5

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice.

For information about the American Diabetes Association's scholarly journals, visit https://diabetesjournals.org/. For more about this podcast, click here.

We are entering an era of choice in terms of diabetes and obesity therapies. Choice is good, but having a keen understanding of each medication is crucial to avoid being overwhelmed. In this special episode of DOC Updates, host Dr. Neil Skolnik explores the latest amylin-based therapies.

This special episode is sponsored with support from Novo Nordisk.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science

Selected References:

Garvey, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2025;393:635-647 doi.org/10.1056/NEJMoa2502081

Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study," The Lancet Diabetes & Endocrinology, 2026; 14, 649-661 doi.org/10.1016/S2213-8587(26)00126-9

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts.

2:20 Our hosts speak with Klara Klein, MD, PhD, assistant professor of medicine at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and Marie Claire Abram, attending physician at Maine Health Medical Center in Portland, Maine. Their article, "Variability in Autoantibody Ordering Patterns Suggests Potential for Diabetes Misclassification," is available at doi.org/10.2337/doc26-0071.

13:10 Next, Jane introduces Miranda Zuniga-Kennedy, MS, a clinical psychology graduate student at WSU. Her article, "Determinants of Cognitive Change Over 1 Year in Older Adults With Type 1 Diabetes," is available at doi.org/10.2337/doc26-0069.

25:05 Finally, Richard and Jane highlight some of their favorite articles from the September-October issue.

•

Chae, et al. "Physical Activity Patterns in Adults Taking Glucagon-Like Peptide-1 Receptor Agonists: An All of Us Cross-Sectional Study," doi.org/10.2337/doc26-0062

•

Descarpentrie, et al. "School Meal Participation, Overall Dietary Intake, and Prediabetes Prevalence Among U.S. Adolescents: Insights From the National Health and Nutrition Examination Survey (2017–2023)," doi.org/10.2337/doc26-0084

•

Bannuru, et al. "Comparative Effectiveness of Continuous Glucose Monitoring Versus Blood Glucose Monitoring in Pregnancy With Diabetes: Systematic Review and Meta-analysis With Trial Sequential Analysis," doi.org/10.2337/doc26-0018

•

March, et al. "Implementation of Diabetes Care Coordination in Schools Across Pediatric Centers in the T1D Exchange Quality Improvement Collaborative," doi.org/10.2337/doc26-0110

•

Adel, et al. "Virtual Diabetes Optimization Program (VDOP) for Veterans With Uncontrolled Diabetes," doi.org/10.2337/doc26-0020

•

Smith-Morris, et al. "Culinary Medicine and Medical Nutrition Therapy Interventions to Improve Glycemic Control in Type 2 Diabetes: A Pragmatic Trial During the COVID-19 Pandemic," doi.org/10.2337/doc26-0048

To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit https://diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Now it is time to look at some specific examples of hypertension. In the final installment of this special three-part series, Dr. Neil Skolnik dives into case studies which are emblematic of typical patient profiles, but ones which also present unique challenges.

This series is sponsored with support from AstraZeneca.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Raymond R. Townsend, MD, Professor of Medicine, Department of Internal Medicine/Renal, University of Pennsylvania School of Medicine

Susan K. Kuchera, MD, Program Director of the Jefferson Health Abington Family Medicine Residency Program and Clinical Associate Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University

Selected references:

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10)

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med 2025;393:1363-74. DOI: 10.1056/NEJMoa2507109

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2025, 00, 1–43 https://doi.org/10.1210/clinem/dgaf284

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103-2116

You know how GLP-1s impact diabetes and weight loss. But what about coronary disease treatment and prevention? Liver disease? Heart failure? Osteoarthritis? Sleep apnea? In this special episode, Dr. Neil Skolnik covers it all, exploring what we do—and do not—know about the expanding scope of GLP-1-based therapies.

This special episode is sponsored with support from Lilly.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Donna Ryan, MD, professor emeritus at the Pennington Biomedical Research Center in Baton Rouge, Louisiana and former president of both the Obesity Society and the World Obesity Federation

References:

The expanding landscape of GLP-1 medicines. Nature Medicine volume 32, pages 47–57 (2026) doi.org/10.1038/s41591-025-04124-5

Weight-loss-independent actions of GLP-1 medicines. Cell Metabolism, 38, 1535-1539 doi.org/10.1016/j.cmet.2026.07.006

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232 doi.org/10.1056/NEJMoa2307563

Welcome to the latest episode (October 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month on DOC Updates:

Zoungas et al; Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. New England Journal of Medicine, 28 August 2026; doi.org/10.1056/NEJMoa2607314

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD), press release

N. Kruger, et al; Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ 2026; 394 doi.org/10.1136/bmj-2026-100011

Dufour, et al; Type 2 Diabetes and Longitudinal Changes in Cortical and Trabecular Bone Density, Microarchitecture, and Strength: The Framingham Study. Diabetes Care 2026; dc260846. doi.org/10.2337/dc26-0846

He, et al; Early Weight Loss in Impaired Glucose Tolerance Is Associated With Reduced Long-term Mortality and Cardiovascular Risk: The Da Qing Diabetes Prevention Outcome Study. Diabetes Care 2026; dc260689. doi.org/10.2337/dc26-0689

Leavens ELS, Pebley K, Smith TT, et al; Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians. JAMA. 2026;336(9):783–790. doi.org/10.1001/jama.2026.13087

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice.

For information about the American Diabetes Association's scholarly journals, visit https://diabetesjournals.org/. For more about this podcast, click here.

Welcome to the latest episode (September 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month on DOC Updates:

Diaz KM, Murdock ME, Serafini MA, et al. Evaluating movement breaks as a public health strategy to mitigate the harms of prolonged sitting: a large-scale pragmatic intervention. British Journal of Sports Medicine 2026;60:1208-1217.

Chorniy, et al. Progression to Diabetes by Adults With Prediabetes Who Use the National Diabetes Prevention Program: A Natural Experiment. Diabetes Care 20 August 2026; 49 (9): 1576–1584. doi.org/10.2337/dc25-2485

Harnois-Leblanc, et al. Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence. Diabetes Care 20 August 2026; 49 (9): 1645–1653. doi.org/10.2337/dc25-2975

Guan, et al. Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank. Diabetes Care 20 August 2026; 49 (9): 1663–1668. doi.org/10.2337/dc26-0797

Guo, et al. Life Course Cumulative BMI Burden From Childhood to Adulthood and Risk of Metabolic Multimorbidity: A 36-Year Prospective Cohort Study. Diabetes Care 20 August 2026; 49 (9): 1567–1575. doi.org/10.2337/dc25-2889

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice.

For information about the American Diabetes Association's scholarly journals, visit https://diabetesjournals.org/. For more about this podcast, click here.

Uncontrolled and resistant hypertension is more common than we think. In the second episode of this special three-part series, Dr. Neil Skolnik discusses management strategies, but also explores our new understanding of aldosterone and its stealth role in hypertension.

This series is supported with support from AstraZeneca.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Payal Kohli, MD, Harvard-educated preventive cardiologist and the Founder and Medical Director of Cherry Creek Heart​ in Aurora Colorado, Associate Adjunct Professor in Cardiology at Johns Hopkins University, and Associate Adjunct Professor in Cardiology at Duke University

Selected references:

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10)

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med 2025;393:1363-74. DOI: 10.1056/NEJMoa2507109

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2025, 00, 1–43 https://doi.org/10.1210/clinem/dgaf284

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103-2116

What is the difference between MASH and MASLD? In this special episode, Dr. Neil Skolnik breaks down these conditions, which affect insulin resistance of the liver, an area of increasing concern for people with diabetes.

This special episode is sponsored with support from Lilly.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Jay Shubrook, DO, Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine

Susan Kuchera, MD, Program Director of the Jefferson Health Abington Family MedicineResidency Program and Associate Clinical Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University.

References:

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease. Gastroenterology, 2026; 171, 164-183

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082

A Clinical Update on MASLD. JAMA Intern Med. 2025;185;(1):105-107. doi:10.1001/jamainternmed.2024.6431

Weight maintenance is a challenging topic for both clinicians and patients. In this special episode, Neil Skolnik is joined by Jamie Almondoz, MD, who discusses the toxic narratives that have historically been part of the weight loss conversation, and the latest strategies for maintaining a healthy weight after the initial loss.

This special episode is sponsored with support from Lilly.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Jamie Almondoz, MD, Professor of Internal Medicine and the Medical Director of the Weight Wellness Program at the University of Texas Southwestern Medical Center and Vice-Chair of the American Board of Obesity Medicine (ABOM)

References:

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. June 2026; 407:2305-2318

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial. JAMA 2021;325;(14):1414-1425

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med 32, 2679–2687 (2026)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022; 24(8): 1553-1564

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates those efforts is essential. In this special episode, Neil Skolnik speaks with Nihar Desai about the challenges of managing chronic kidney disease and diabetes.

This special episode is sponsored with support from Bayer.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Nihar Desai, MD, MPH, Associate Professor of Medicine and Associate Chief of the Section of Cardiovascular Medicine at Yale University School of Medicine, Investigator at the Center for Outcomes Research and Evaluation, and Medical Director for Value Innovation at the Yale New Haven Health System.

Selected references:

Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1) :S246–S260

Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229

Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts.

1:15 Our hosts speak with Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director of Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington School of Medicine. She is an author of the article "SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis," available at doi.org/10.2337/doci26-0001.

8:50 Next, Richard introduces Alexander Turchin, MD, MS, Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is an author of "Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022," available for free at doi.org/10.2337/doc26-0027.

17:05 Richard and Jane highlight special material available in the latest issue of Diabetes, Obesity, and CardioMetabolic CARE.

•

"Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026," available for free at doi.org/10.2337/doci26-0003

•

"Employment and Diabetes: A Statement of the American Diabetes Association," available for free at doi.org/10.2337/doc25-0092.

23:40 Finally, Richard and Jane highlight some of their favorite articles from the July-August issue.

•

Vidovic, et al. Behavior Modifications From CUT-DM, Including Lifestyle Modification and Self-Efficacy doi.org/10.2337/doc25-0093

•

Chan, et al. Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes doi.org/10.2337/doc26-0019

•

Bannuru, et al. RAAS Inhibitors for the Primary Prevention of CKD in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-analysis doi.org/10.2337/doci25-0014

•

Dimentstein, et al. Goals of Care Among Caregivers of Youths With Type 1 Diabetes doi.org/10.2337/doc26-0035

To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit https://diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month on DOC Updates:

Hirsh Elhence, Jennifer L. Dodge, Stephen Fuest, et al. National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study. Ann Intern Med. [Epub 2 June 2026]. doi:10.7326/ANNALS-25-05287

Eva Johnsen, et al. Achieving at Least 15% Weight Loss Within 2 Years of Type 2 Diabetes Diagnosis Is Associated With Lower Risks of Macrovascular and Microvascular Complications: A U.K. Cohort Study. Diabetes Care 20 July 2026; 49 (8): 1480–1489. doi.org/10.2337/dc26-0937

Carel W. le Roux, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England Journal of Medicine June 2026 DOI: 10.1056/NEJMoa2600751

Yu Wang, Shichao Tang, Xilin Zhou, Ping Zhang. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022. Diabetes Care 20 July 2026; 49 (8): 1414–1419. https://doi.org/10.2337/dc25-2040

Jelle M. Beernink, et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial. Diabetes Care 20 July 2026; 49 (8): 1434–1441. https://doi.org/10.2337/dc26-0882

Welch M, Forst T, Jia W et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. The Lancet, 2026; 408, 125-140 DOI: 10.1016/S0140-6736(26)00800-7

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice.

For information about the American Diabetes Association's scholarly journals, visit https://diabetesjournals.org/. For more about this podcast, click here.

In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure.

This special episode is sponsored with support from AstraZeneca.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Minesh Rajpal, MD, Attending Nephrologist and Hypertension Specialist at the Southwest Kidney Institute

References:

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10)

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957

In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE—come together to discuss key highlights and groundbreaking research presented at the 2026 meeting.

They share expert insights across the bench-to-bedside spectrum, including basic science, clinical research, and the latest in diabetes care and education. Tune in for thoughtful reflections on what this year's findings mean for clinical practice and future research.

Available now across all ADA professional podcast channels.

Featured Podcasts:

•

DOC Updates – ADA's podcast for primary care

•

Diabetes Care "On Air" – From ADA's clinical research journal, Diabetes Care

•

DiabetesBio – From ADA's flagship research journal, Diabetes

•

The Points of CARE - The official podcast of Diabetes, Obesity, and CardioMetabolic CARE

Join the Discussion with:

•

Alice Cheng, MD – Co-host of Diabetes Care "On Air"

•

Kirk Habegger, PhD – Co-host of DiabetesBio

•

Michael Rickels, MD, MS – Co-host of Diabetes Care "On Air"

•

Neil Skolnik, MD – Co-host of DOC Updates and Diabetes Day by Day

•

Kevin Williams, PhD – Co-host of DiabetesBio

•

Richard Beaser, MD – Co-host of The Points of CARE

🔗 Learn more about ADA's full podcast portfolio: https://diabetesjournals.org/journals/pages/podcasts

Subscribe to DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE on Apple Podcasts, Amazon Music, Spotify, or your preferred platform.

Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing understanding of this cholesterol-carrying lipoprotein.

This special episode is sponsored with support from Lilly.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

EPISODE NOTES

Special Edition: Special Edition: Lp(a) & CV Risk

In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Michael Wilkinson, who goes over the history of Lp(a), the current guidelines, and the importance of screening.

This special episode is sponsored with support from Lilly.

Presented by:

-Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

-Michael Wilkinson, MD, Associate Professor of Medicine at University of California San Diego Health, and Director of the advanced lipid treatment program at UC San Diego Health, Board of Directors of the National Lipid Association and Associate editor of the American Journal of Preventive Cardiology

References:

-The American Heart Association PREVENT Online Calculator

-Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects – Circulation 2025; 151:400-415

-2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation Volume 153, Issue 17, 28 April 2026; Pages e1154-e1276

Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therapy can have over daily basal insulin.

This special episode is sponsored with support from Novo Nordisk.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Aaron King, MD. Trained in the United States Navy in Family Medicine and certified by the American College of Diabetology, Dr. King practices outpatient diabetes management in San Antonio, Texas.

Selected references:

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med 2023;389:297-308

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. N Engl J Med 2025;393:325-335

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area.

This special episode is sponsored with support from Bayer.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research

Selected References:

Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260

Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229

Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month on DOC Updates:

•

Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9

•

Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0

•

Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026

•

Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7

•

Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492

Presented by:

•

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

•

John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

For information about the American Diabetes Association's scholarly journals, visit https://diabetesjournals.org/. For more about this podcast, visit About Diabetes Core Update.